Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 2, 1998, Pages 111-117

  Vigushin, David M ^a   Poon, Grace K ^b   Boddy, Alan ^c   English, Jacqueline ^a   Halbert, Gavin W ^d   Pagonis, Christos ^e   Jarman, Michael ^b   Coombes, R Charles ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

D Limonene; Farnesyltransferase inhibitor; Natural monoterpene; Pharmacokinetics

Indexed keywords

DIHYDROPERILLIC ACID; DRUG METABOLITE; LIMONENE; LIMONENE 1,2 DIOL; PERILLIC ACID; UNCLASSIFIED DRUG; UROTERPENOL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG TISSUE LEVEL; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYCLOHEXENES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TERPENES; TREATMENT OUTCOME;

EID: 0031834303     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050793     Document Type: Article

References (21)

1. Ariazi EA, Gould MN (1996) Identifying differential gene expression in monoterpene-treated mammary carcinomas using subtractive display. J Biol Chem 271: 29286
2. Chander SK, Lansdown AG, Luqmani YA, Gomm JJ, Coope RC, Gould MN, Coombes RC (1994) Effectiveness of combined limonene and 4-hydroxyandrostenedione in the treatment of NMU-induced rat mammary tumors. Br J Cancer 69: 879
3. Croteau R (1987) Biosynthesis and catabolism of monoterpenes. Chem Rev 87: 929
4. Crowell PL, Gould MN (1994) Chemoprevention and therapy of cancer by D-limonene. Crit Rev Oncog 5: 1
5. Crowell PL, Chang RR, Ren Z, Elson CE, Gould MN (1991) Selective inhibition of isoprenylation of 21-26 kDa proteins by the anticarcinogen D-limonene and its metabolites. J Biol Chem 266: 17679
6. Crowell PL, Lin S, Vedejs E, Gould MN (1992) Identification of metabolites of the antitumor agent D-limonene capable of inhibiting protein isoprenylation and cell growth. Cancer Chemother Pharmacol 31: 205
7. Crowell PL, Ren Z, Lin S, Vedejs E, Gould MN (1994) Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem Pharmacol 47: 1405
8. Crowell PL, Elson CE, Bailey HH, Elgebede A, Haag JD, Gould MN (1994) Human metabolism of the experimental anticancer agent D-limonene. Cancer Chemother Pharmacol 35: 31
9. Elson CE, Maltzman TH, Boston JL, Tanner MA, Gould MN (1988) Anticarcinogenic activity of D-limonene during the initiation and promotion progression stages of DMBA-induced rat mammary carcinogenesis. Carcinogenesis 9: 331
10. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anti-cancer agents in mouse, rat, dog, monkey and man. Cancer Chemother Rep 50: 219
11. Gould MN (1997) Cancer chemoprevention and therapy by monoterpenes. Environ Health Perspect 105: 977
12. Haag JD, Gould MN (1994) Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother Pharmacol 34: 477
13. Haag JD, Lindstrom MJ, Gould MN (1992) Limonene-induced regression of mammary carcinomas. Cancer Res 52: 4021
14. Igimi H, Nishimura M, Kodama R, Ide H (1974) Studies on the metabolism of D-limonene (p-mentha-1,8-diene). I. The absorption, distribution and excretion of D-limonene in rats. Xenobiotica 4: 77
15. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ (1992) Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89: 6403
16. Kodama R, Yano T, Furukawa K, Noda K, Ide H (1976) Studies on the metabolism of D-limonene (p-mentha-1,8-diene). IV. Isolation and characterization of new metabolites and species differences in metabolism. Xenobiotica 6: 377
17. Maltzman TH, Hurt LM, Elson CE, Tanner MA, Gould MN (1989) The prevention of nitrosomethylurea-induced mammary tumors by D-limonene and orange oil. Carcinogenesis 10: 781
18. Miller AB, Hoogstraten B, Staquet M, Berard D (1981) Reporting results of cancer treatment. Cancer 47: 207
19. National Toxicology Program (NTP) (1990). Toxicology and carcinogenesis studies of D-limonene NTP TR 347. United States Department of Health and Social Services, Public Health Service, National Institutes of Health, Washington DC
20. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649
21. Poon GK, Vigushin D, Griggs LJ, Rowlands MG, Coombes RC, Jarman M (1996) Identification and characterization of limonene metabolites in patients with advanced cancer by liquid chromatography/mass spectrometry. Drug Metab Dispos 24: 565